In short
Nothing available to any human being has been shown to undo ageing, and no drug, supplement, drip or hormone has been shown in a trial to slow human ageing itself. What the published evidence does support is changing how fast decline happens, and the list is short and unglamorous: not smoking, with quitting before 40 removing about 90% of the excess risk of death from continued smoking (Jha et al., NEJM 2013); cardiorespiratory fitness, where the fittest group had an adjusted all-cause mortality hazard ratio of 0.20 against the least fit (Mandsager et al., JAMA Network Open 2018); 150–300 minutes a week of moderate activity plus muscle-strengthening work on at least two days (WHO 2020 guidelines; Momma et al., Br J Sports Med 2022); control of blood pressure, blood glucose and LDL cholesterol; around seven hours of sleep; and correcting hearing and vision. Roughly 45% of dementia worldwide is attributed to 14 modifiable risk factors, including hearing loss, high LDL cholesterol, hypertension, diabetes, smoking, inactivity, depression, social isolation and untreated vision loss (Lancet Commission on dementia, 2024). The commonest wrong assumption is that persistent tiredness in your thirties is ageing: it is far more often vitamin D or B12 deficiency, iron-deficiency anaemia, an undiagnosed thyroid disorder, obstructive sleep apnoea or depression, each of which is a diagnosis rather than a decade. Products sold as slowing ageing have generally either failed their trials or never been tested against any clinical outcome, and technical noise alone has produced deviations of up to nine years between replicate measurements of the same sample across six prominent research epigenetic clocks (Higgins-Chen et al., Nature Aging 2022). This page is general health information drawn from published evidence. It is not an offer of treatment, it recommends no drug, hormone or supplement, and it is not a substitute for seeing a doctor. Written and reviewed by Dr. A. Ameer Jahan, MBBS, MD, TNMC 28017, AJ Subaitha Medical Centre, Egmore, Chennai, reviewed 15 August 2026.
At what age does ageing start?
There is no single switch and no single age. Different systems start changing at different times, at different speeds, and the change is measurable long before anything is noticeable. Asking "when does it start" produces a misleading answer; asking "what is changing now, and how fast" produces a useful one.
The table below is organised by system rather than by birthday. Each row is the earliest point at which change is reliably measurable in published data, not the point at which a person feels it.
| System | When measurable change begins | What actually changes | Source |
|---|---|---|---|
| Ovarian reserve and female fertility | Late twenties, faster after 35 | Falling follicle number and oocyte quality; menopause follows at a pooled mean of about 46.6 years in India | Systematic review and meta-analysis of age at menopause in India, 2021 |
| Skeletal muscle mass and strength | Mid-thirties onward | Roughly 1–2% of muscle mass a year, with strength falling faster than mass | Indian Consensus on Sarcopenia, 2025 |
| Cardiorespiratory fitness | Third decade onward if untrained | Falls with age in sedentary adults and is largely modifiable by training | Exercise-testing cohort data summarised in Mandsager et al., 2018 |
| Blood pressure, glucose and lipids | Thirties onward in Indian adults | Weighted Indian prevalence: dyslipidaemia 81.2%, hypertension 35.5%, prediabetes 15.3%, diabetes 11.4% | ICMR-INDIAB-17, Lancet Diabetes Endocrinol 2023 |
| Skin | Tracks cumulative ultraviolet dose, not birthdays | Photoageing accumulates; daily sunscreen of SPF 15 or higher slowed accumulation by 24% over 4.5 years | Hughes et al., Annals of Internal Medicine 2013 |
| Bone (women) | Fastest in the first 3–4 years after menopause | Accelerated resorption; an earlier menopause starts this clock earlier | Indian Menopause Society osteoporosis guidance, 2019–2020 |
| Hearing and vision | Fifth decade onward, gradually | Both are on the list of modifiable dementia risk factors when left uncorrected | Lancet Commission on dementia, 2024 |
Can ageing be undone?
No. No intervention has been shown to undo ageing in a human being, and no trial has demonstrated it. Claims of having taken years off a person's age generally come from single unblinded self-experiments measured on tests whose measurement error is wider than the effect being claimed, and scientists working in the field have said publicly that such results are being misrepresented.
The distinction that matters is between undoing something and changing its rate. Rate can be changed, and the evidence for that is solid. A person who is fit, not smoking, with controlled blood pressure and glucose, sleeping adequately and hearing and seeing properly declines more slowly than a person who is not. That is a real finding with large effect sizes behind it. It is not the same claim as restoration, and any page that blurs the two is selling something.
It is also worth naming what the science actually says when it is quoted at you. The twelve hallmarks of ageing (López-Otín et al., Cell 2023) are a research framework, and the authors' own criteria for inclusion were established largely in laboratory organisms. Naming a hallmark, naming a molecule that touches it in a cell line, and implying a benefit to a person is the commonest move in this market, and it is not evidence.
What actually slows how fast you age?
The honest answer is a short list of ordinary things that have been tested against death and disease rather than against a laboratory marker. Nothing on the list is a product, and none of it is new.
| What | What the evidence shows | Type of evidence | Source and year |
|---|---|---|---|
| Not smoking, or quitting | Smokers lose at least a decade of life expectancy; quitting before 40 reduced the excess risk of death from continued smoking by about 90% | Large prospective cohort | Jha et al., NEJM 2013 |
| Cardiorespiratory fitness | Adjusted all-cause mortality hazard ratio 0.20 in the fittest versus the least fit; no upper limit of benefit found | Cohort, 122,007 patients | Mandsager et al., JAMA Netw Open 2018 |
| Aerobic activity | 150–300 min/week moderate associated with 19–25% lower all-cause mortality; 300–600 min/week with 26–31% lower, with no further gain and no harm above that | Prospective cohort, 30 years | Lee et al., Circulation 2022 |
| Muscle-strengthening activity | 10–17% lower risk of all-cause mortality, cardiovascular disease, cancer and diabetes, independent of aerobic activity; benefit peaked at 30–60 min/week | Systematic review and meta-analysis | Momma et al., Br J Sports Med 2022 |
| Blood pressure control | A systolic target below 120 mmHg versus below 140 mmHg cut all-cause mortality by 27% over a median 3.26 years, with more hypotension, syncope, electrolyte disturbance and acute kidney injury in the intensive arm | Randomised trial, 9,361 adults | SPRINT, NEJM 2015; final report 2021 |
| LDL cholesterol control | Across trials of LDL-lowering treatment, each 1.0 mmol/L reduction in LDL cholesterol was associated with proportional reductions of roughly 20–25% in major vascular events over the treatment period | Meta-analysis of 27 randomised trials | Cholesterol Treatment Trialists' Collaboration, Lancet 2012 |
| Sleep of about seven hours | Under 7 hours: hazard ratio 1.14 for all-cause mortality; 9 hours or more: 1.34. The long-sleep arm is heavily confounded because illness causes long sleep | Meta-analysis | GeroScience 2025 |
| Body weight | Each 5 kg/m² of BMI above 25 associated with 29–39% higher all-cause mortality in never-smokers free of disease at baseline | 239 prospective studies, 10.6 million people | Global BMI Mortality Collaboration, Lancet 2016 |
| Social connection | Social isolation associated with 29% higher mortality, loneliness 26%, living alone 32%, after adjustment for confounders | Meta-analysis | Holt-Lunstad et al., Perspect Psychol Sci 2015 |
| Correcting hearing | No slowing of cognitive decline in the trial overall; 48% slowing in the pre-specified higher-risk subgroup. Worth doing for hearing; unproven for cognition | Randomised trial, 977 adults | ACHIEVE, Lancet 2023 |
| Correcting vision | Cataract extraction associated with about 29% lower dementia risk; observational only, no randomised evidence | Prospective cohort | Lee et al., JAMA Intern Med 2022 |
| Alcohol | For adults aged 15–39 the intake associated with least health risk is zero or close to zero | Global burden analysis | GBD 2020 Alcohol Collaborators, Lancet 2022 |
Read the list as a whole rather than row by row. These are risk factors, not treatments, and every one of them is a matter of ordinary living rather than of anything bought. That is the comparison every product discussed further down this page is being measured against.
How much exercise does the evidence actually support?
Two separate things are being measured here and they are not interchangeable. Aerobic activity and muscle-strengthening work each carry independent mortality associations, which is why the guidelines ask for both rather than letting one substitute for the other.
| Type | Amount in the evidence | Associated finding |
|---|---|---|
| Moderate aerobic activity | 150–300 min/week | 19–25% lower all-cause mortality (Lee et al., 2022) |
| Moderate aerobic activity | 300–600 min/week | 26–31% lower all-cause mortality; no additional benefit and no harm above this (Lee et al., 2022) |
| Vigorous aerobic activity | 75–150 min/week | About 19% lower all-cause mortality (Lee et al., 2022) |
| Muscle-strengthening work | 2 or more days a week, all major muscle groups | WHO 2020 guideline for all adults; older adults add balance and functional training |
| Muscle-strengthening work | 30–60 min/week | Point of maximal mortality benefit; beyond about 60 min/week no further mortality benefit demonstrated (Momma et al., 2022) |
One measurable number is worth knowing because it replaces guesswork. Cardiorespiratory fitness measured on a treadmill predicted death more strongly than smoking, hypertension or diabetes in the Cleveland Clinic cohort of 122,007 patients (Mandsager et al., 2018), which is an unusual finding for any single measurement to produce. One honest caveat applies to all of it: these dose-response curves come overwhelmingly from American, European, East Asian and Australasian cohorts, and India's metabolic baseline differs enough that transferring them exactly is an assumption rather than a finding.
Why am I always tired at 30? Is that ageing?
Almost never. Fatigue is one of the commonest reasons adults consult a general outpatient clinic anywhere, and the list of things that explain it is a list of diagnoses, not decades. Ageing does not produce sudden, persistent, months-long exhaustion in an otherwise healthy person in their thirties; something else usually does.
Vitamin D deficiency is the largest single candidate in this country, though the size of the problem is easy to overstate. The most widely quoted Indian figures — 46.5% deficient and a further 26% insufficient across 2.2 million test results between 2019 and January 2025, with South India the most affected region at 51.6% — come from a commercial pathology dataset published by Metropolis Healthcare Limited in 2025. Those are test results from people who presented for testing, so they describe how often deficiency is found on testing, not how common it is in the Indian population, and the true population figure is likely to be lower. B12 deficiency is common on predominantly vegetarian diets. Iron-deficiency anaemia, undiagnosed hypothyroidism, obstructive sleep apnoea and depression complete the list, and every one of them is identifiable and treatable.
What follows from that is unremarkable and useful: fatigue that has lasted more than a few weeks is a reason for an ordinary consultation and a small number of ordinary blood tests. It is not a reason for an infusion, a panel of novel markers or a supplement bought on the strength of a symptom. A deficiency that has been measured can be corrected under medical supervision; a deficiency that has been assumed usually cannot.
Do you lose muscle after 40, and can you stop it?
Muscle mass falls at roughly 1–2% a year from the mid-thirties, and strength falls faster than mass does (Indian Consensus on Sarcopenia, 2025). In India the consequences arrive earlier than most people expect. A 2024 cross-sectional study in western India found sarcopenia in about 10% of middle-aged adults, with 4.2% severe (PLOS Global Public Health, 2024).
Inadequate protein intake was an independent risk factor in that Indian data. That is a dietary pattern question rather than a supplement question, the evidence sits with total daily protein from ordinary food alongside resistance training, and it is stronger than the evidence behind anything named in the section below.
The practical significance is not appearance. Muscle strength and cardiorespiratory fitness are the two measurable capacities that track most closely with independence in later decades, and resistance work is the intervention shown to move them. Someone who is thin but weak, the pattern often described as thin-fat, with normal body weight and high truncal fat — is not protected by the number on the scale, and abdominal obesity affects 39.5% of Indian adults against 28.6% with generalised obesity (ICMR-INDIAB-17, 2023).
How do I protect my memory as I get older?
Asked as a memory question, this is answered as a blood-vessel and sensory question. The 2024 Lancet Commission attributes about 45% of dementia worldwide to 14 modifiable risk factors: low education, hearing loss, high LDL cholesterol, depression, traumatic brain injury, physical inactivity, diabetes, smoking, hypertension, obesity, excessive alcohol, social isolation, air pollution and untreated vision loss. Vision loss and high LDL were the two added in 2024.
So the evidence-based answer to "how do I protect my memory" is that hearing and vision should be tested and corrected, blood pressure and lipids and glucose should be controlled, activity should be maintained, and depression and social isolation should be taken seriously. None of that is a memory intervention in the way the market uses the phrase, and all of it has outcome data behind it.
Two honesty markers belong here. The ACHIEVE trial of hearing intervention was null in its overall population and positive only in a pre-specified higher-risk subgroup, so hearing correction is clearly worth doing for hearing and remains promising but unproven for cognition. The cataract-surgery finding is observational, and confounding by health-seeking behaviour is entirely plausible.
One further finding is reported here because readers encounter it and because it is frequently overstated. A natural experiment using the age cut-off for eligibility in a national zoster vaccination programme found new dementia diagnoses reduced by 3.5 percentage points in absolute terms, a 20.0% relative reduction over seven years (Eyting et al., Nature 2025). No randomised trial has tested dementia as an endpoint, the mechanism is unknown, and quasi-experimental designs of this kind establish an association under assumptions rather than an effect. Nothing on this page recommends any vaccine or any other product; immunisation is a decision for a person and their own doctor.
Ordinary forgetfulness that the person notices themselves is usually not dementia; memory change that family members notice is a different matter and is covered in the closing section.
Do Indians age faster than people in the West?
On the measures that can actually be compared, the useful observation is not that ageing runs faster but that the metabolic conditions which shape later decades are extraordinarily common, and mostly silent when they first appear.
ICMR-INDIAB-17 (Lancet Diabetes & Endocrinology 2023), which surveyed 113,043 adults across 31 states and union territories, is the baseline every reader in Chennai is standing on: 11.4% diabetes, 15.3% prediabetes, 35.5% hypertension, 28.6% generalised obesity, 39.5% abdominal obesity and 81.2% dyslipidaemia. Those are the conditions that determine how the next three decades go, and most of them produce no symptoms at the point when they could most usefully be found.
The demographic backdrop is changing at the same time. India's population aged 60 and over is projected to reach 20.8% by 2050 (UNFPA India Ageing Report, 2023). For a reader in Chennai the realistic goal is fewer years spent ill, and the window in which that is decided opens earlier than most Western health content assumes.
Why do I look older than my age?
One exploratory study of 202 Indian women, graded by 693 assessors, found that observers over-estimated their ages and that the drivers differed by decade: skin lightness parameters dominated in the thirties, while from the forties onward wrinkles around the eye area, the glabella and the corners of the mouth were also drivers (Cosmetics, 2018). That study was conducted by a cosmetics company, and this article treats funding source as material elsewhere, so it is reported here with the same qualification: it is a single industry-funded observational study, not a settled finding.
The modifiable inputs are cumulative ultraviolet exposure, smoking and sleep. The only randomised trial of sunscreen against skin ageing found that daily use of SPF 15 or higher on the head, neck, arms and hands produced 24% less skin ageing on microtopography grading over 4.5 years compared with discretionary use (Hughes et al., Annals of Internal Medicine 2013). Two qualifiers are part of the finding rather than footnotes to it: the trial showed slowed accumulation and not removal of existing photoageing, and the same trial's beta-carotene arm showed no effect on photoageing at all.
Beyond that, skin is a dermatology subject. An assessment of pigmentation, texture or any cosmetic question belongs with a dermatologist rather than with further reading here.
At what age does menopause start in India?
This section reports published evidence only and contains no clinical direction; it sits outside the author's registered field and any decision belongs with a gynaecologist.
| Population | Reported age at menopause | Source |
|---|---|---|
| Indian women overall | Pooled mean 46.64 years (95% CI 44.83–48.44) | Systematic review and meta-analysis of Indian studies, 2021 |
| Western India | About 46.2 years | Regional estimate within the same systematic review, 2021 |
| South Indian women | About 46.1 years | Pan-India study of menopause age and determinants, 2016 |
The clinical relevance of the age is not cosmetic. Bone resorption is fastest in the first three to four years after menopause, and cardiovascular risk changes after it, so the age at which menopause occurs sets when both clocks start (Indian Menopause Society guidance, 2019–2020). Menopausal hormone therapy is a treatment for menopausal symptoms and for bone loss and is not a treatment for ageing; published positions hold that for most healthy symptomatic women under 60 and within ten years of menopause the benefit-risk balance is favourable (NAMS position statement, 2022). Which is to say it is a consultation, not a decision to be made from a search result.






